Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

Phase 2 Completed 28 enrolled University of Kansas Medical Center Pfizer · collab

NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to learn whether daily use of Duavee® is accepted and tolerated by peri- and post-menopausal women at moderate risk for development of breast cancer.

Timeline

Start: 2016-05
Primary completion: 2019-01
Completion: 2019-06

Publications

Results Fabian CJ, Nye L, Powers KR, Nydegger JL, Kreutzjans AL, Phillips TA, Metheny T, Winblad O, Zalles CM, Hagan CR, Goodman ML, Gajewski BJ, Koestler DC, Chalise P, Kimler BF. Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Risk Biomarkers in High-Risk Women: A Pilot Study. Cancer Prev Res (Phila). 2019 Oct;12(10):711-720. doi: 10.1158/1940-6207.CAPR-19-0315. Epub 2019 Aug 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bazedoxifene	Other / unclassified	20 mg	Oral
Subject	conjugated estrogens	Other / unclassified	0.45 mg	Oral

Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation

Summary

Timeline

Publications

Drugs

Indications